Eterna Therapeutics Appoints Matt Angel, Ph.D. as Chief Executive Officer and President
05 January 2023 - 12:30AM
Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the
“Company”), a biopharmaceutical company using advanced cell
engineering technology to develop transformational new medicines,
today announced the appointment of Matt Angel, Ph.D. as Chief
Executive Officer (“CEO”) and President. Dr. Angel has served as
Interim CEO and President of Eterna since May 2022 and will
continue to serve on the Company's Board of Directors.
“The Board and I are delighted that Matt will serve as CEO and
President in a permanent capacity, and we remain confident in his
continued ability to lead Eterna as the company executes on its
core strategy of advancing Eterna’s mRNA cell engineering
platform,” said Charles Cherington, Chairman of the Board of
Directors of Eterna. “While Interim CEO and President, Matt has
guided Eterna’s efforts to realize the full potential of this
powerful suite of technologies.”
“I am thrilled to continue leading and serving Eterna as CEO and
President, and I am proud of all that we have accomplished over the
past six months,” said Matt Angel, Ph.D. “As we move into 2023, we
believe that Eterna is uniquely positioned to deploy its extensive
in-licensed patent portfolio covering key mRNA, induced pluripotent
stem (iPS) cell and gene editing technologies. A top priority for
2023 will be to leverage our in-licensed patent portfolio to drive
value creation for our stakeholders.”
Dr. Angel joined Eterna as Interim CEO and President in May 2022
and was appointed a member of the Board of Directors. He is an
experienced biotechnology entrepreneur and executive with deep
experience in intellectual property protection and licensing,
contract negotiation, including collaboration and licensing
agreements, and has raised more than $150 million through grants,
equity financings, and M&A. A pioneer in mRNA technology, Dr.
Angel is a prolific inventor with more than 100 patents covering
mRNA, nucleic acid delivery, gene editing, and cell reprogramming
technologies. In addition to his role at Eterna, Dr. Angel serves
as Co-Founder, Chairman and CEO of Factor Bioscience Inc., and
Co-Founder and Scientific Advisory Board Chair of Exacis
Biotherapeutics. He previously served as Co-Founder and Chief
Scientific Officer of Novellus Therapeutics, which was acquired by
Eterna in 2021. Dr. Angel received his B.S.E. from Princeton
University and Ph.D. from the Massachusetts Institute of
Technology.
About Eterna TherapeuticsEterna’s mission is to
realize the potential of cell engineering to provide patients with
transformational new medicines. The Company has in-licensed a
portfolio of over 100 patents covering key cell engineering
technologies, including what it believes are the most widely used
methods for therapeutic gene editing currently in clinical
development. For more information, please visit
www.eternatx.com.Forward-Looking StatementsThis
press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
which are intended to be covered by the safe harbor provisions of
the Private Securities Litigation Reform Act of 1995.
Forward-looking statements are any statements that are not
statements of historical fact and may be identified by terminology
such as “believe,” “could,” “estimate,” “anticipate,” “expect,”
“plan,” “possible,” “potential,” “project,” “will” or other similar
words and the negatives of such words. Forward-looking statements
are based on current beliefs and assumptions that are subject to
risks and uncertainties and are not guarantees of future
performance. Actual results could differ materially from those
stated or implied in any forward-looking statement as a result of
various factors, including, but not limited to, uncertainties
related to: (i) the evolution of Eterna’s business model into a
platform company focused on mRNA, iPS cell and gene editing
technologies; (ii) Eterna’s ability to successfully,
cost-effectively and efficiently develop its technology and
products; (iii) Eterna’s ability to successfully commence clinical
trials of any products on a timely basis or at all; (iv) Eterna’s
ability to successfully fund and manage the growth of its
development activities; (v) Eterna ’s ability to obtain regulatory
approvals of its products for commercialization; and (vi)
uncertainties related to the impact of the COVID-19 pandemic on the
business and financial condition of Eterna, including on the timing
and cost of its clinical trials. You should not rely upon
forward-looking statements as predictions of future events. The
forward-looking statements made in this communication speak only as
of the date on which they were made, and Eterna does not undertake
any obligation to update the forward-looking statements contained
herein to reflect events that occur or circumstances that exist
after the date hereof, except as required by applicable law.
Factors that may cause Eterna’s actual results to differ from those
expressed or implied in forward-looking statements contained in
this press release are more fully disclosed in Eterna’s periodic
public filings with the U.S. Securities and Exchange Commission,
particularly under the heading “Risk Factors” in Eterna’s Annual
Report on Form 10-K for the year ended December 31, 2021, as
amended, as well as under similar headings in Eterna’s subsequently
filed Quarterly Reports on Form 10-Q and Current Reports on Form
8-K.
Investor Relations
Contact:investors@eternatx.com
Media Contact:EternaPR@westwicke.com
Source: Eterna Therapeutics Inc.
Eterna Therapeutics (NASDAQ:ERNA)
Historical Stock Chart
From Mar 2024 to Apr 2024
Eterna Therapeutics (NASDAQ:ERNA)
Historical Stock Chart
From Apr 2023 to Apr 2024